WRF
FOLD

Waddell & Reed Financial’s Amicus Therapeutics FOLD Stock Holding History

Waddell & Reed Financial’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-949,306
Closed -$21.9M – 487
2020
Q4 		$21.9M Buy
949,306
+1,289
+0.1% +$26.4K 0.05% 351
2020
Q3 		$13.4M Buy
948,017
+129,025
+16% +$1.88M 0.03% 362
2020
Q2 		$12.3M Buy
+818,992
New +$9.98M 0.03% 362

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Waddell & Reed Financial's FOLD Position: Q1 2021 in Review

Waddell & Reed Financial sold out of Amicus Therapeutics (FOLD) in Q1 2021, closing a stake of 949,306 shares — an estimated $21.9M sold.

Waddell & Reed Financial first reported a position in FOLD in Q2 2020 and held it in 3 quarters. The position peaked at $21.9M in Q4 2020. 259 funds tracked by Wall St. Rank hold FOLD as of Q1 2021.

  • Waddell & Reed Financial reported no remaining Amicus Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Waddell & Reed Financial sold 949,306 Amicus Therapeutics shares in Q1 2021, an estimated $21.9M.
  • Waddell & Reed Financial first reported a position in Amicus Therapeutics in Q2 2020 and held it in 3 quarters.
  • Waddell & Reed Financial's Amicus Therapeutics position peaked at $21.9M in Q4 2020.
  • 259 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2021.

Based on Waddell & Reed Financial's 13F filing for Q1 2021, filed 12 May 2021.